^
Association details:
Biomarker:PD-L2 overexpression
Cancer:Prostate Cancer
Drug Class:PD-L1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Immunogenomic Profiling and Classification of Prostate Cancer Based on HIF-1 Signaling Pathway

Excerpt:
The results indicate that HIF-1_H exhibited the highest expression of PD-L1, PD1, and PD-L2, while HIF-1_L had the lowest expression of PD-L1, PD1, and PD-L2 (Kruskal–Wallis test, P < 0.05) (Figures 4A,B). This suggests that PCa subtype HIF-1_H may have a better response to anti-PD-L1 immunotherapy...
DOI:
https://doi.org/10.3389/fonc.2020.01374